Recombinant Cell Bioassay For Rapid Detection Of Estrogenic And Antiestrogenic Chemicals
Tech ID: 21060 / UC Case 2011-003-0
The ability of a wide variety of compounds to disrupt normal endocrine homeostasis, and potentially, the physiological and reproductive capacity of an organism, is of great concern. Researchers at the University of California, Davis developed a novel, cell-based bioassay that detects compounds that impact the estrogen receptor signaling pathway.
This stably transfected recombinant human cell line responds to estrogenic chemicals with the induction of luciferase gene expression in a time-, dose-, and chemical specific manner and responds to antiestrogenic chemicals with the inhibition of estrogen-dependent gene expression.
Non-exclusive licenses are available for UC's property rights in this cell bioassay and patent rights in the luciferase reporter gene as it is utilized within the cell bioassay.
This cell bioassay system also contains components owned by the Promega Corporation. Licensees can acquire Promega permissions relevant to practicing this invention by executing a contract services agreement directly with Promega. UC can provide interested parties with a draft license agreement as well as a sample of the Promega contract services agreement.
Applications and Advantages
This novel cell-based bioassay allows rapid and inexpensive screening, identification and characterization of estrogenic and antiestrogenic endocrine disrupting chemicals and extracts containing such chemicals. The assay can also provide an estimate of the relative estrogenic/antiestrogenic potency of a target/test chemical or an extract containing these chemicals.
- University of California Davis (UCD). "Test for hormone-disrupting chemicals gets global seal of approval." ScienceDaily. - 01/29/2013
- Rogers JM, and Denison MS. 2000. Recombinant cell bioassays for endocrine disruptors: development of a stably transfected human ovarian cell line for the detection of estrogenic and anti-estrogenic chemicals. In Vitr Mol Toxicol. 13(1):67-82.
- Rogers JM, and Denison MS. 2002. Analysis of the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human ovarian carcinoma BG-1 cells. Mol Pharmacol. 61(6):1393-403.
- Klein GP, Hodge EM, Diamond ML, Yip A, Dann T, Stern G, Denison MS, and Harper PA. 2006. Gas-phase ambient air contaminants exhibit significant dioxin-like and estrogen-like activity in vitro. Environ Health Perspect. 114(5):697-703.
- Denison, Michael S.
- Rogers, Jane M.
endocrine disruptors, estrogenic chemicals, antiestrogenic chemicals, estrogen receptor signaling pathway
ADDITIONAL TECHNOLOGIES BY THESE INVENTORS
PEOPLE WHO VIEWED THIS ALSO VIEWED THESE TECHNOLOGIES BY OTHER INVENTORS
- Amplified Recombinant Cell Bioassay For The Detection Of Dioxin And Related Ah Receptor Ligands
- Biomimetic Solid Separator
- Method to Identify Candidates for Hormone Replacement Therapy in Women Undergoing the Menopausal Transition
- Anti-SynDig1 Monoclonal Antibody
- New Compounds For the Treatment Of Osteoporosis, Promoting Bone Fracture Healing, and Improving Pro-engraftment of Stem Cells to Bone